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Background: The sensitivity of needle-core biopsy (NCB) in diagnosing phyllodes tumours has only been
addressed by a handful of small studies. The aim of this study was to analyse the sensitivity of NCB in the
diagnosis of phyllodes tumours and to compare this to the sensitivity of other commonly performed
investigations. A secondary aim was to assess the effect of various patient and disease factors on the rate
of false negative test results.
Methods: Pathology databases were interrogated to identify all patients with the SNOMED term M-9020
or the word phyllodes in specimen reports. Excisional specimen reports were matched to prior FNAC
reports, NCB reports and imaging reports.
Results: Ninety-one patients had a conﬁrmed phyllodes tumour on excision. The sensitivity of FNAC, NCB
and imaging for diagnosing phyllodes tumours was 40%, 63% and 65% respectively. The sensitivity of
imaging and NCB was greater for borderline and malignant lesions. Combining cytohistological and
radiological tests improved sensitivity to 76%. A younger age was associated with a greater false negative
rate for all tests. Borderline and malignant phyllodes tumours were signiﬁcantly associated with
advancing age and greater lesion size on imaging and histology.
Conclusions: This is the largest report to date assessing the sensitivity of NCB in the diagnosis of phyllodes
tumours. Increased sensitivity in the diagnosis of phyllodes tumours can be achieved by combining
cytohistological and radiological test results. The novel association between younger age and false
negative results warrants further investigation. The most likely explanation is a reluctance to diagnose
phyllodes tumours in young women given the increased prevalence of cellular ﬁbroadenomas in this age
group.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Phyllodes tumours are ﬁbroepithelial lesions of the breast
comprising less than 1% of breast neoplasms.1 The importance of
these lesions is that 10e15% are malignant with a similar
percentage falling into a borderline category,2 and even benign
phyllodes tumours have a propensity for local recurrence if note-needle aspiration cytology;
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ciates Ltd. Published by Elsevier Ltproperly excised.3 Treatment is by surgical excision, ideally with
a 1 cm margin of normal breast tissue for borderline or malignant
tumours.
Other benign ﬁbroepithelial lesions, namely ﬁbroadenomas, can
be managed by non-operative treatment following conﬁrmation
with core biopsy, thus avoiding the morbidity of excision. This is
recommended as ﬁbroadenomas can regress with time and there is
low malignant potential.4 It is therefore important to be able to
distinguish between ﬁbroadenomas and phyllodes tumours.
Pathologically, phyllodes tumours are characterised by
epithelial-lined cleft-like spaces with a hypercellular stroma,
organised into leaf-like fronds. Fibroadenomas, on the other hand,
have a hypocellular stroma and scant pleomorphism. The stroma
can exhibit focal or diffuse hypercellularity, especially in women
less than 20 years of age. These changes form part of a continuum
with no clearly deﬁnable cut-off, making distinction between
ﬁbroadenomas and phyllodes tumours difﬁcult.d. All rights reserved.
Table 1
The results of FNAC and NCB sampling in conﬁrmed phyllodes tumours.
FNAC Frequency (%) NCB Frequency (%)
C1 6 (24) B1 2 (3)
C2 9 (36) B2 22 (34)
C3 7 (28) B3 39 (60)
C4 2 (8) B4 2 (3)
C5 1 (4) B5 e
Total 25 Total 65
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denomas5with a pushing border. Inmalignantphyllodes, themargin
is inﬁltrative with ﬁbrosarcomatous changes in the stroma. Diag-
nostic criteria exist to distinguish between benign, borderline and
malignant phyllodes tumours, based on the criteria: pushing or
inﬁltratingmargin, stromal cellularity, stromal overgrowth, necrosis,
cellular atypia, number of mitoses per ten high-power ﬁelds.6
Triple assessment is the standard means of evaluation of all
breast lumps and involves a combination of clinical, radiological
and either cytological or histological assessment. Over the last
decade there has been a move from ﬁne needle aspiration cytology
(FNAC) towards needle core biopsy (NCB) in the diagnosis of breast
lesions, due to the limitations of FNAC. NCB reports in the United
Kingdom are given a pathology category classiﬁcation between B1
and B5 to aid in their role of pathology assessment. Lesions
suggestive of a phyllodes tumour are classiﬁed as B3.6
The aim of our study was to assess the sensitivity of NCB within
the context of triple assessment in all patients diagnosed with
phyllodes tumours across two hospitals over a 13 year period and
relate false negative results to any patient or disease factors.
2. Methods
Patients from two hospitals with dedicated breast services in the UK were
included in this study: Good Hope Hospital (GHH), Sutton Coldﬁeld and Queen
Elizabeth Hospital (QEH), Edgbaston. The pathology databases from these hospitals
were interrogated to identify all patients with specimens classiﬁed with the
following SNOMED terms: T-0400 (breast) and M-9020 (phyllodes tumour). A
search was also performed for the term phyllodes appearing in summary text of the
report. All such patients between April 1996 and July 2009 were identiﬁed and the
pathology reports for excisional specimens and any prior NCB and FNAC samples
were obtained. Radiology reports and clinic letters were retrieved along with
demographic data.
The reports of NCB and FNAC samples were analysed for all patients with
conﬁrmed phyllodes tumours, based on the excisional pathology report. For NCB
samples, the use of ultrasound guidance, the number of cores and total length of
fragments were noted. Patient age, laterality of lesion, radiology score (R1 to R5),
maximum dimension of lesion on imaging and lesion size on excision were tabu-
lated. All subsequent statistical analysis was performed using SPSS Statistics v19
(IBM corporation).
The diagnostic sensitivity of NCB and FNAC in the diagnosis of phyllodes
tumours was calculated. The ability of the factors mentioned above to predict false
negative biopsy results was analysed using the Chi-squared test for categorical
variables and theManneWhitney test for continuous variables. B1, C1 and R1 results
were excluded from these analyses. Similarly, factors associated with benign versus
borderline or malignant phyllodes tumours were analysed using the Chi-squared
and ManneWhitney tests followed by an ordinal logistic regression analysis for
independence.
P-values of less than 0.05 were considered to be statistically signiﬁcant.
3. Results
A total of 143 patients were identiﬁed, of which 91 patients had
conﬁrmed phyllodes tumour on excision (37 from GHH, 54 from
QEH). A further 2 patients had excisional histology reported as
equivocal for phyllodes. The 91 cases were classiﬁed as malignant
(6 cases), borderline (11 cases) or benign (74 cases). All patients
were female with a median age of 40 years (range: 16e93 years).
The follow-up period ranged from 2 to 13 years. All excisions
were either reported as adequately excised (61 cases) or underwent
cavity shaving to obtain clear margins (30 cases). Therewere 3 local
recurrences during the follow-up period. These 3 patients all had
a benign phyllodes tumour with clear margins at initial excision,
conﬁrmed as benign recurrent disease at further operation. There
was one death due to unrelated causes during the follow-up period.
3.1. FNAC and NCB sensitivity
Twenty-ﬁve patients with conﬁrmed phyllodes tumours had
prior FNAC; 65 patients had prior NCB (see Table 1). AssumingFNAC/NCB category of 3 or more as a positive test result, the
diagnostic sensitivity of FNAC was 40% and NCB, 63%. The sensi-
tivity of both FNAC and NCB was improved for malignant and
borderline lesions, see Table 2.
Ultrasound-guidance was used to undertake NCB in 23 of the 65
patients (35%) and the two B1 results were both obtained using
a freehand technique. Three ultrasound-guided NCBs had initially
been performed freehand but were repeated using image-guidance
due to an incongruous result (B1 in two cases and B2 in one case)
with the rest of the triple assessment. None of the FNACs were
performed using ultrasound-guidance.
3.2. Imaging
Eighty-two of the 91 cases of conﬁrmed phyllodes cases had
prior imaging. Eighty-one cases had a prior ultrasound; 53 cases
had a prior mammogram. The overall sensitivity of imaging in
diagnosing phyllodes tumours was 65%.
All patients with borderline and malignant phyllodes tumours
underwent imaging or FNAC/NCB sampling. Only 66 out of 74
patients with benign phyllodes tumours had either imaging or
sampling. The frequency of positive tests for FNAC/NCB and
imaging in combination against tumour classiﬁcation for conﬁrmed
phyllodes tumours is shown in Table 3.
Both imaging and FNAC/NCB investigations were negative for
thirteen patients with benign phyllodes and one patient with
a borderline phyllodes tumour which raises the issue of the indi-
cation for excision biopsy in these cases. Three of these 14 patients
were initially diagnosed with ﬁbroadenoma and underwent exci-
sion biopsies 6 or more months after the investigations due to
documented increases in lesion size. The remaining 11 excision
biopsies were for lesions all under 30 mm in size. Excision biopsy
took place within 4 months of investigations and, although no
reasons were documented, this timeframe suggests that lesions
were excised due to patient choice.
3.3. Factors associated with false negative test results
For all tests (NCB, FNAC and imaging), the mean age was
signiﬁcantly less in the false negative group compared to the true
positive group (see Table 4).
3.4. Factors associated with phyllodes classiﬁcation
Progression along the phyllodes spectrum from benign to
borderline to malignant was associated with increasing patient age
and increasing lesion size on imaging and histology (see Table 5).
Ordinal logistic regression analysis revealed that both age (P¼ 0.05)
and lesion size (P < 0.05), measured on imaging or at histology, are
independently associated with phyllodes classiﬁcation.
4. Discussion
Differentiating phyllodes tumours from ﬁbroadenoma is of
utmost importance given that the treatment and prognosis of these
Table 2
Sensitivity of FNAC, NCB and imaging in the diagnosis of phyllodes tumours.
Classiﬁcation FNAC sensitivity NCB sensitivity Imaging sensitivity
Benign 9 from 23 cases (39%) 30 from 53 cases (57%) 40 from 65 cases (62%)
Borderline 1 from 1 case (100%) 9 from 10 cases (90%) 9 from 11 cases (82%)
Malignant 0 from 1 case (0%) 5 from 5 cases (100%) 4 from 6 cases (67%)
Overall 10 from 25 cases (40%) 41 from 65 cases (63%) 53 from 82 cases (65%)
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nomas can be favoured and it is possible for these lesions to regress
with time.4 On the other hand, phyllodes tumours recur if not
excised with a clear margin and a proportion are malignant with
the potential to metastasise.1 In our study, out of 91 excised phyl-
lodes tumours, 6.6% were malignant and 11.1% were categorised as
borderline. This is consistent with other studies.7 Three of 74 (4.1%)
benign phyllodes tumours recurred locally despite complete
histological excision and this is entirely in keeping with the results
of others.8
Obtaining a correct diagnosis of a phyllodes tumour by triple
assessment involves a combination of clinical, radiological and
either cytological or histological assessment. The majority of
phyllodes tumours arise in women aged between 35 and 55 years,
a slightly older group than that for ﬁbroadenomas.8 In our study
both the mean and median ages were 41 years. Phyllodes tumours
are typically larger than ﬁbroadenomas and a history of rapid
growth may be reported.7
The imaging modalities most commonly employed are
mammography and ultrasonography. A review of mammograms in
99 phyllodes tumours found that, even though some differences
were noted in lesion opacity and margin characteristics between
phyllodes tumours and ﬁbroadenomas, mammographic features
were non-discriminatory.9 Sonographically, a lobulated shape,
heterogeneous echo pattern and absence of microcalciﬁcation have
been shown to be signiﬁcant independent characteristics dis-
tinguishing phyllodes tumours from ﬁbroadenomas.10 There is,
however, a substantial overlap of these features between the two
lesions. Equally, imaging characteristics cannot distinguish benign
and malignant phyllodes tumours.11 The sensitivity of imaging at
diagnosing an equivocal or suspicious lesion over a ﬁbroadenoma
ranges from 31 to 58%.7,12,13We found an overall imaging sensitivity
of 65%. The majority of our patients underwent ultrasound imaging
(89%) and our relatively higher imaging sensitivity may be
explained by the recent improvements in breast ultrasound.14
The reported sensitivity of FNAC for diagnosing phyllodes
tumours is reported as ranging from 25 to 70%15 and our results are
consistent with this. Although the one malignant phyllodes tumour
which underwent prior cytology was not correctly diagnosed by
FNAC (C1), this was most likely due to sampling error.
The main advantage of needle-core biopsy (NCB) is that it
obtains a core of tissue which can be examined histologically
without the need for open breast biopsy. It causes less trauma and
disﬁgurement than open biopsy and can be performed in the out-
patient setting. Due to the presence of both epithelial and
stromal elements in the needle core, increased use of NCB in the
breast clinic was expected to improve upon the ability of tripleTable 3
Sensitivity of FNAC/NCB in combination with imaging in conﬁrmed phyllodes tumours.
FNAC/NCB and imaging positive Eith
Benign 22 from 66 cases (33%) 53 f
Borderline 9 from 11 cases (82%) 10 f
Malignant 3 from 6 cases (50%) 6 fro
All 34 (41%) 69 (assessment to distinguish phyllodes tumours from ﬁbroadenomas.1
However, studies to date which have speciﬁcally addressed the
issue of NCB sensitivity in the diagnosis of phyllodes tumours have
been small.
One study of 17 core biopsies in phyllodes tumours conﬁrmed
by excision reported a NCB report of B3 or more in 12 cases.7 Two
small studies reported amuch higher sensitivity of 81%13 and 92%,16
although the total number of conﬁrmed phyllodes tumours was
only 16 and 19 respectively. In a study of 13 conﬁrmed phyllodes
tumours, 10 of the 13 NCB reports were equivocal rather than
favouring a ﬁbroadenoma, yielding a sensitivity of 77%.17 However,
only just over half the patients with an equivocal NCB report in this
study underwent excisional biopsy. Use of image-guided NCB in 12
patients with conﬁrmed phyllodes reported a sensitivity of 83%.12
Sampling error using a freehand technique is a reported phenom-
enon18 and considering this was favoured in just over two-thirds of
cases in our study, could have resulted in a lower sensitivity in our
patient group.
Comparatively larger studies of 27 patients19 and 36 patients20
with conﬁrmed phyllodes tumours and prior core biopsies re-
ported sensitivities of 61% and 67% respectively. The latter study
went on to assess key histological characteristics that differed
between excised ﬁbroadenoma and phyllodes tumours. Stromal
cellularity, stromal overgrowth, fragmentation and entrapped fat
were found to be reproducible and signiﬁcantly more common in
phyllodes tumours. A more recent analysis of core biopsy features
associated with phyllodes tumours again reported marked stromal
cellularity and overgrowth as factors that exclusively predicted
phyllodes on excision.21 They also found a statistically signiﬁcant
association between number of mitoses and ill-deﬁned lesional
borders on NCB and conﬁrmed phyllodes and no such association
with entrapped fat. The study design does not allow for a direct
extrapolation of NCB sensitivity. Logistic regression analysis has
shown that combining the patient age with mitotic index can
correctly differentiate phyllodes tumours from ﬁbroadenomas in
95% cases using speciﬁc cut-off values obtained from receiver-
operator characteristic curves.22 The largest study in the litera-
ture reported 54 NCB results in patients with conﬁrmed phyllodes
tumours with a sensitivity of 44%.23
An alternative approach to assessing histological differences
between ﬁbroadenoma and phyllodes tumours has been under-
taken by identifying excised phyllodes tumours which were
initially described as ﬁbroadenoma on NCB.24 The authors give
a descriptive account of increased stromal cellularity and over-
growth, increased tissue fragmentation and increased numbers
of mitoses. Immunohistochemistry was performed for Ki-67
(a proliferation marker), cleaved caspase-3 (a marker forer FNAC/NCB or imaging positive Both investigations negative
rom 74 cases (72%) 13 from 66 cases (20%)
rom 11 cases (91%) 1 from 11 cases (9%)
m 6 cases (100%) 0 from 6 cases (0%)
76%) 14 (17%)
Table 4
Factors associated with false negative test results. Figures quoted as mean  one standard deviation.
NCB FNAC Imaging
False negative True positive P False negative True positive P False negative True positive P
Age 38.1  10.1 44.6  14.2 0.046 26.8  11.3 37.4  7.6 0.011 31.7  9.9 42.4  13.6 0.001
Laterality L:R 7:15 18:23 0.350 2:7 4:6 0.405 13:19 21:32 0.927
Hospital GHH:QE 11:10 12:30 0.061 3:6 5:5 0.463 12:20 24:29 0.482
Size (imaging) 28.8  11.6 41.0  45.0 0.246 25.0  13.9 21.2  9.5 0.689 25.2  11.9 42.9  45.5 0.073
Size (histology) 20.4  7.3 32.1  26.1 0.497 24.5  12.5 19.4  7.7 0.248 21.5  8.5 33.1  26.5 0.306
Number of cores 4.0  0.8 4.3  1.3 0.272
Total core length 60.0  5.0 44.1  25.2 0.851
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ORIGINAL RESEARCHapoptosis) and p53 (an abnormal tumour suppressor protein). Only
Ki-67 was found to be increased in phyllodes tumours over
ﬁbroadenomas. This has also been shown by other authors21,25
together with increased topoisomerase 2a (a DNA structure-
modifying enzyme) and reduced CD34 (an adhesion molecule
found in some human tumours).
Our study of 91 patients with conﬁrmed phyllodes tumours, 65
of whom had a prior NCB is the largest reported in the literature to
date. We found the overall sensitivity of NCB to be 63% e higher for
borderline and malignant phyllodes tumours which, despite being
intuitive, is not well documented in the literature.
When results of triple assessments for ﬁbroepithelial lesions are
reviewed, an estimate of the sensitivity of the key components of
such an assessment should be known. To this end, we have shown
the sensitivity of FNAC, NCB and imaging in differentiating phyl-
lodes from ﬁbroadenomas to be 40%, 63% and 65% respectively and
this is consistent with the literature. We have also shown that by
combining test results, as occurs in triple assessment, a sensitivity
of 76% can be attained. There was a minority group of patients with
both negative imaging and sampling results who were found to
have a phyllodes tumour on excision. Delayed excision was
undertaken for 3 patients due to increases in lesion size but the
other 11 patients had the lesions excised based on negative test
results. We therefore sought any factors that could identify patients
at risk of phyllodes tumour despite false negative test results.
To this end, a younger age was associated with a higher false
negative rate for all tests. For FNAC and NCB, this may reﬂect
a propensity for stromalhypercellularity to be reported as a cellular or
juvenile ﬁbroadenoma, rather than a phyllodes tumour. Equally,
knowledge of the difference in age groups between the two lesions,
may sway a radiologist or pathologist towards a more benign diag-
nosis. Our study did not independently review cytohistological diag-
noses nor assess the inter-observer reliability. Distinction between
phyllodes tumour and ﬁbroadenomas is hampered by the lack of
acceptedhistological, cytological and radiological criteria aswell as by
the subjective nature of available tests and samplingbias. It is possible
that, in future, histological markers may be identiﬁed that can help
differentiate the two lesions. Similarly progress in breast imaging, is
likely to result in improved sensitivity for phyllodes diagnosis.
We have shown a statistically signiﬁcant increase in lesion size
as phyllodes tumours progress from a benign to malignant classi-
ﬁcation. One should beware large or rapidly growing ﬁbroepithelialTable 5
Factors associated with phyllodes classiﬁcation. Figures quoted as mean  one
standard deviation.
Benign Borderline Malignant P
Age 33.6  10.0 40.6  16.1 52.3  11.9 0.008
Laterality L:R 29:45 4:7 4:2 0.400
Hospital GHH:QE 33:41 3:8 1:5 0.256
Size (imaging) 23.4  8.5 41.9  7.5 80.6  89.9 0.001
Size (histology) 20.8  8.7 29.7  5.0 60.0  46.4 0.01lesions as both are predictive of phyllodes tumours.1 Large tumours
are also subject to biopsy sampling error, even though our data did
not show an association between number of cores or total core
length with a lower false negative rate. Variable areas of stromal
cellularity exist within phyllodes tumours with some areas
resembling ﬁbroadenoma. Similarly, the majority of the biopsymay
contain an epithelial component and consequently, a lack of
stromal component prevents proper histological distinction
between phyllodes and ﬁbroadenomas.15 Evenwith an appropriate
biopsy, diagnosis is subjective. In particular, assessment of stromal
cellularity is subject to observer as well as sampling bias.21
In summary, combining FNAC/NCB results with imaging can
improve diagnostic sensitivity, validating the triple assessment
approach for ﬁbroepithelial lesions. Lesions with imaging or NCB/
FNAC results consistent with a phyllodes tumour should therefore
be excised. Lesions diagnosed as ﬁbroadenomas that subsequently
increase in size should be excised. Younger age is associated with
higher false negative rates for NCB, FNAC and imaging. Advancing
age and increasing lesion size are associated with phyllodes clas-
siﬁcation from benign through to malignant categories.
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